AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests


AnPac Bio validating approved Covid-19 antibody test. (Credit: Belova59 from Pixabay.)

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States announced today that the Company has been validating an approved COVID-19 antibody test, which has received the FDA’s Emergency Use Authorization, for commercial use in its San Jose, California lab since the second quarter of 2020, with expected validation completion in the second half of 2020.

As COVID-19 cases are still on the rise and no clear short-term containment in sight, COVID-19 tests will likely have both long-term and widespread demand.  As such, the Company is fully committed to validating the aforementioned approved COVID-19 antibody test.

AnPac Bio’s CEO, Dr. Chris Yu, commented, “AnPac Bio is entering into a fast growing phase of rapid new products and services development. Following the successful launch of our immunology product and CDA/ct-DNA combination test product in the first half of this year, the pending commercialization of an approved COVID-19 antibody test will be another major new product and service which AnPac Bio will offer that will accelerate our revenue growth. Our CLIA and CAP accredited clinical laboratory in the U.S. allows us to take advantage of commercial market opportunities in the U.S. by offering additional laboratory services while also continuing our research and development on our CDA technology.”

Source: Company Press Release